Characterization of pathogenic human monoclonal autoantibodies against GM-CSF

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 19, 2013, Pages 7832-7837

  Wang, Yanni ^a   Thomson, Christy A ^a,g   Allan, Lenka L ^a   Jackson, Linda M ^a   Olson, Melanie ^a,h   Hercus, Timothy R ^b   Nero, Tracy L ^c   Turner, Amanda ^d   Parker, Michael W ^c,e   Lopez, Angel L ^b   Waddell, Thomas K ^f   Anderson, Gary P ^d   Hamilton, John A ^d   Schrader, John W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF TORONTO   (Canada)

^g AMGEN INC   (United States)

^h StemCell Technologies Inc   (Canada)

Author keywords

Autoantibody; Autoimmune; Biotherapeutic; Cytokine; Three dimensional model

Indexed keywords

AUTOANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; EPITOPE MAPPING; HUMAN; LUNG ALVEOLUS PROTEINOSIS; MEMORY CELL; MULTIPLE SCLEROSIS; NEOPLASM; PAIN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SOMATIC MUTATION; T LYMPHOCYTE;

AUTOANTIBODY; AUTOIMMUNE; BIOTHERAPEUTIC; CYTOKINE; THREE-DIMENSIONAL MODEL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD11B; AUTOANTIBODIES; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; EPITOPE MAPPING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC MEMORY; INHIBITORY CONCENTRATION 50; KINETICS; MUTATION; NEUTROPHILS; POINT MUTATION; PULMONARY ALVEOLAR PROTEINOSIS; SURFACE PLASMON RESONANCE; T-LYMPHOCYTES;

EID: 84877339165     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1216011110     Document Type: Article

References (56)

1. Silverstein AM (2001) Autoimmunity versus horror autotoxicus: The struggle for recognition. Nat Immunol 2(4): 279-281.
2. Zenewicz LA, Abraham C, Flavell RA, Cho JH (2010) Unraveling the genetics of autoimmunity. Cell 140(6): 791-797.
3. Burnet FM (1972) A reassessment of the forbidden clone hypothesis of autoimmune disease. Aust J Exp Biol Med Sci 50(1): 1-9.
4. Watson CT, Breden F (2012) The immunoglobulin heavy chain locus: Genetic variation, missing data, and implications for human disease. Genes Immun 13(5): 363-373.
5. Breden F, et al. (2011) Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS ONE 6(3):e16857.
6. Foreman AL, Van de Water J, Gougeon M-L, Gershwin ME (2007) B cells in autoimmune diseases: Insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmunity Rev 6(6): 387-401.
7. Di Niro R, et al. (2012) High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med 18(3): 441-445.
8. Rowley D, Jenkin CR (1962) Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity. Nature 193: 151-154.
9. Kitamura T, et al. (1999) Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 190(6): 875-880.
10. Uchida K, et al. (2004) High-affinity autoantibodies specifically eliminate granulocytemacrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103(3): 1089-1098.
11. Sakagami T, et al. (2009) Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 361(27): 2679-2681.
12. Trapnell BC, Carey BC, Uchida K, Suzuki T (2009) Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol 21(5): 514-521.
13. Metcalf D (2008) Hematopoietic cytokines. Blood 111(2): 485-491.
14. Handman E, Burgess AW (1979) Stimulation by granulocyte-macrophage colonystimulating factor of Leishmania tropica killing by macrophages. J Immunol 122(3): 1134-1137.
15. Hamilton JA, Stanley ER, Burgess AW, Shadduck RK (1980) Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J Cell Physiol 103(3): 435-445.
16. Lopez AF, et al. (1986) Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78(5): 1220-1228.
17. Hercus TR, et al. (2009) The granulocyte-macrophage colony-stimulating factor receptor: Linking its structure to cell signaling and its role in disease. Blood 114(7): 1289-1298.
18. Bonfield TL, Kavuru MS, Thomassen MJ (2002) Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 105(3): 342-350.
19. Carey B, Trapnell BC (2010) The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 135(2): 223-235.
20. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306(20): 1189-1196.
21. Toyka KV, et al. (1977) Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med 296(3): 125-131.
22. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195): 667-671.
23. Uchida K, et al. (2007) GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 356(6): 567-579.
24. Rathanaswami P, et al. (2005) Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun 334(4): 1004-1013.
25. Hercus TR, et al. (1994) Identification of residues in the first and fourth helices of human granulocyte-macrophage colony-stimulating factor involved in biologic activity and in binding to the alpha- and beta-chains of its receptor. Blood 83(12): 3500-3508.
26. Hansen G, et al. (2008) The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134(3): 496-507.
27. Patino E, et al. (2011) Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα. Structure 19(12): 1864-1875.
28. Laver WG, Air GM, Webster RG, Smith-Gill SJ (1990) Epitopes on protein antigens: Misconceptions and realities. Cell 61(4): 553-556.
29. Thomson CA, et al. (2008) Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus. EMBO J 27(19): 2592-2602.
30. Schmidt AG, et al. (2013) Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci USA 110(1): 264-269.
31. Steidl S, Ratsch O, Brocks B, Dürr M, Thomassen-Wolf E (2008) In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 46(1): 135-144.
32. Watanabe M, et al. (2007) Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 581(10): 2017-2021.
33. Uchida K, et al. (2009) Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 113(11): 2547-2556.
34. Adelstein S, et al. (1991) Induction of self-tolerance in T cells but not B cells of transgenic mice expressing little self antigen. Science 251(4998): 1223-1225.
35. Ottonello L, et al. (2002) Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: Role of adenosine and proinflammatory cytokines. Rheumatology (Oxford) 41(11): 1249-1260.
36. Bazin R, St-Amour I, Laroche A, Lemieux R (2010) Activated cryptic granulocytemacrophage colony-stimulating factor autoantibodies in intravenous immunoglobulin preparations. Blood 115(2):431.
37. Felix NJ, et al. (2007) Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 8(4): 388-397.
38. Kisand K, et al. (2010) Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 207(2): 299-308.
39. Puel A, et al. (2010) Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207(2): 291-297.
40. Di Zenzo G, et al. (2012) Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. J Clin Invest 122(10): 3781-3790.
41. Dal Porto JM, Haberman AM, Kelsoe G, Shlomchik MJ (2002) Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J Exp Med 195(9): 1215-1221.
42. Lingwood D, et al. (2012) Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489(7417): 566-570.
43. Akkaraju S, Canaan K, Goodnow CC (1997) Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. J Exp Med 186(12): 2005-2012.
44. Li J, et al. (2006) Human antibodies for immunotherapy development generated via a human B cell hybridoma technology. Proc Natl Acad Sci USA 103(10): 3557-3562.
45. Hamilton JA (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7): 533-544.
46. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA (2001) Blockade of collageninduced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): Requirement for GM-CSF in the effector phase of disease. Arthritis Res 3(5): 293-298.
47. McQualter JL, et al. (2001) Granulocyte macrophage colony-stimulating factor: A new putative therapeutic target in multiple sclerosis. J Exp Med 194(7): 873-882.
48. Codarri L, et al. (2011) RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6): 560-567.
49. El-Behi M, et al. (2011) The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12(6): 568-575.
50. Iversen PO, et al. (1997) Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 90(12): 4910-4917.
51. Bayne LJ, et al. (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6): 822-835.
52. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) Oncogenic Krasinduced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6): 836-847.
53. Schweizerhof M, et al. (2009) Hematopoietic colony-stimulating factors mediate tumor- nerve interactions and bone cancer pain. Nat Med 15(7): 802-807.
54. Cook AD, et al. (2013) Granulocyte-macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic pain. Ann Rheum Dis 72(2): 265-270.
55. Thomson CA, et al. (2012) Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol 3:87.
56. McLean GR, et al. (2005) Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J Immunol 174(8): 4768-4778.